Effects of liraglutide versus sitagliptin on circulating cardiovascular biomarkers, including circulating progenitor cells, in individuals with type 2 diabetes and obesity: Analyses from the LYDIA trial

The mechanisms behind the beneficial cardiovascular effects of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) compared with dipeptidyl peptidase‐4 inhibitors (DPP4is) remain largely unknown, despite both targeting the incretin pathway to improve glycaemic control. In these prespecified seconda...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes, obesity & metabolism obesity & metabolism, 2021-06, Vol.23 (6), p.1409-1414
Main Authors: Ahmad, Ehtasham, Waller, Helen L., Sargeant, Jack A., Webb, M'Balu A., Htike, Zin Zin, McCann, Gerry P., Gulsin, Gaurav, Khunti, Kamlesh, Yates, Tom, Henson, Joseph, Davies, Melanie J., Webb, David R.
Format: Article
Language:English
Subjects:
Antidiabetics
Arteriosclerosis
Biomarkers
Body mass index
Diabetes
Diabetes mellitus (non-insulin dependent)
Dipeptidyl-peptidase IV
GLP-1 receptor agonists
Glucagon
Glycosylation
liraglutide
Nitric oxide
Obesity
Peptidase
Progenitor cells
randomized active‐comparator trial
sitagliptin
Stem cells
stromal cell‐derived factor‐1‐alpha
Tumor necrosis factor
Tumors
type 2 diabetes
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The mechanisms behind the beneficial cardiovascular effects of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) compared with dipeptidyl peptidase‐4 inhibitors (DPP4is) remain largely unknown, despite both targeting the incretin pathway to improve glycaemic control. In these prespecified secondary analyses of the LYDIA trial, we examined the impact of the GLP‐1RA liraglutide (1.8 mg once‐daily) and the DPP4i sitagliptin (100 mg once‐daily) on circulating cardiovascular biomarkers associated with atherosclerotic risk, including circulating progenitor cells (CPCs). LYDIA was a 26‐week, randomized, active‐comparator trial in 61 adults with type 2 diabetes and obesity (mean ± SD: age 43.8 ± 6.5 years, body mass index 35.3 ± 6.4 kg/m2, HbA1c 7.5% ± 0.83% [58.5 ± 9.1 mmol/mol]). Vascular endothelial growth factor (VEGF) and stromal cell‐derived factor‐1‐alpha (SDF‐1ɑ), both of which are implicated in endothelial function, were higher at 26 weeks with liraglutide therapy compared with sitagliptin (mean between‐group difference [95% CI]: 77.03 [18.29, 135.77] pg/mL, p = .010; and 996.25 [818.85, 1173.64] pg/mL, p
ISSN:1462-8902
1463-1326
DOI:10.1111/dom.14343